A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Trial Details

NCT ID
NCT06072781
Phase
PHASE3
Sponsor
Verastem, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • avutometinib
  • Defactinib
  • Pegylated liposomal doxorubicin
  • Paclitaxel
  • Letrozole
  • Anastrozole
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sacramento, California, United States|38.58157,-121.4944
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Patients may be eligible for inclusion in the study if they meet the following criteria:
  • Histologically proven LGSOC (ovarian, fallopian, peritoneal)
  • Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test.
  • Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastro…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →